In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biovitrum: A New Flavor of Spin-Off

Executive Summary

Pharmacia spin-off Biovitrum, like other biotechs born out of Big Pharma, has found favor with investors seeking experienced management and advanced programs. But Biovitrum's size, cash flow, and independence appear to make it more attractive still.

Related Content

Intendis: Mid-Sized Specialist Spawns Small Specialist
Bayer: Out of Trouble Come Opportunities
Product Focus Takes Europe Back to Its Roots
Product Focus Takes Europe Back to Its Roots
Investing Warburg Pincus Style
Nycomed: Changing (Private) Hands
Igeneon: Staying Close to Home
Big Pharma Spin-Offs are in Favor, says MPM's Michael Steinmetz
BioXell: A New Beginning for Italian Biotech


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts